Year-end Sale % OFF 
Abstract
Interpatient variability in tacrolimus requirements are large and influenced by multiple factors including cytochrome P450 (CYP) genetics, specifically by CYP3A5 and to a lesser extent CYP3A4. Tacrolimus dosing tailored to CYP genotype has been shown to shorten time to therapeutic range in kidney transplant but data in heart transplant recipients is sparse and findings are variable. We recently implemented weight and genotype-based initial tacrolimus dosing in our heart transplant program. The objective of this study is to examine the impact of genetically tailored tacrolimus dosing on achieving therapeutic trough levels.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
